The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007–2012)

BACKGROUND: Information about treatment protocols, adverse effects and outcomes with intrapleural recombinant tissue plasminogen activator (rTPA) use in horses with fibrinous pleuropneumonia is limited. HYPOTHESIS/OBJECTIVES: Describe factors that contribute to clinical response and survival of hors...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomlinson, J.E., Byrne, E., Pusterla, N., Magdesian, K. Gary, Hilton, H.G., McGorum, B., Davis, E., Schoster, A., Arroyo, L., Dunkel, B., Carslake, H., Boston, R.C., Johnson, A.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
EQUID
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858032/
https://www.ncbi.nlm.nih.gov/pubmed/26256909
http://dx.doi.org/10.1111/jvim.13594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858032/
https://www.ncbi.nlm.nih.gov/pubmed/26256909
http://dx.doi.org/10.1111/jvim.13594

Ejemplares similares